Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31591969 | 0.72 | MGLL (0.36) | MGLLGSK3AGSK3BALDH1A1LMNA | |
| SCHEMBL63145 | 0.67 | MGLL (0.39) | MGLLGSK3AGSK3BALDH1A1LMNA | |
| SCHEMBL63146 | 0.65 | MGLL (0.38) | MGLLGSK3AGSK3BALDH1A1LMNA | |
| SCHEMBL29050725 | 0.65 | MGLL (0.50) | MGLLGSK3AGSK3BALDH1A1LMNA | |
| SCHEMBL709659 | 0.62 | PARL (0.61) | MGLLALDH1A1LMNAMAPTPKM | |
| SCHEMBL25436194 | 0.60 | MGLL (1.00) | MGLLGSK3AGSK3BALDH1A1LMNA | |
| SCHEMBL36966 | 0.60 | — | — | |
| SCHEMBL4887533 | 0.60 | MGLL (0.38) | MGLLGSK3AGSK3BALDH1A1LMNA | |
| SCHEMBL157324 | 0.58 | MGLL (0.50) | MGLLGSK3AGSK3BALDH1A1LMNA | |
| SCHEMBL28676621 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794274-A1 | POSITIVE WORKING LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PROCESS FOR PREPARING LITHOGRAPHIC PRINTING PLATE | Eastman Kodak Company (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013094321-A1 | POSITIVE WORKING LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PROCESS FOR PREPARING LITHOGRAPHIC PRINTING PLATE | EASTMAN KODAK COMPANY (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY LTD. (AU) | 2008-10-16 | — | — | US | disclosed |
| EP-1879564-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | Astrum Therapeutics Pty, Ltd. (AU) | 2008-01-23 | — | — | EP | disclosed |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | ASTRUM THERAPEUTICS PTY LTD (AU) | 2006-11-09 | — | — | US | disclosed |
| WO-2006110477-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY. LTD. (AU) | 2006-10-19 | — | — | WO | disclosed |
| WO-2002062859-A2 | RADICAL POLYMERIZABLE COMPOSITIONS CONTAINING POLYCYCLIC OLEFINS | LOCTITE (US) | 2002-08-15 | — | — | WO | disclosed |
| US-6268108-B1 | MIXTURE OF COMPOUND FORMING ACID UPON EXPOSURE OF ACTINIC RADIATION, COMPOUND CAPABLE OF CROSSLINKING, DYE AND SOLVENT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | IAPP, BCL2, AMY2A | MGLL 1550/4885GSK3A 1339/4885GSK3B 893/4885 |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | IAPP, BCL2, AMY2A | MGLL 1550/4885GSK3A 1339/4885GSK3B 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.